Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.

[en] Denosumab has recently been shown to be safe and to significantly reduce the risk of vertebral, hip and non-vertebral fractures in the "Fracture REduction Evaluation of Denosumab in Osteoporosis every 6Months" (FREEDOM) Trial. Besides the clinical profile of a new drug, it becomes increasingly important to assess whether the drug represents good value for money. This study aims to examine the potential cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women. An updated version of a validated Markov microsimulation model was used to estimate the cost (euro2009) per quality-adjusted life-year (QALY) gained of a 3-year denosumab treatment compared with no treatment. The model was populated with cost and epidemiological data for Belgium from a health-care perspective and the base-case population was defined from the FREEDOM Trial. The effect of denosumab after treatment cessation was conservatively assumed to decline linearly over 1year. Uncertainty was investigated using one-way and probabilistic sensitivity analyses. In particular, additional analyses were performed in populations (over 60years) where osteoporosis medications are currently reimbursed in many European countries, i.e. with bone mineral density (BMD) T-score</=-2.5 or prevalent vertebral fracture. In the base-case analysis, the cost per QALY gained of denosumab compared with no treatment was estimated at euro28,441. This value decreased to euro15,532 and to euro11,603 for women with a BMD T-score of -2.5 or prevalent vertebral fracture, respectively. Additional analyses showed that the cost-effectiveness of denosumab fall below commonly accepted threshold of euro30,000per QALY gained for women with a BMD T-score </=-2.5 or prevalent vertebral fracture, over the entire age range examined (60-80years). The results were robust under a wide range of plausible assumptions. In conclusion, this study suggests, on the basis of currently available data, that denosumab is cost-effective compared with no treatment for postmenopausal Belgian women with low bone mass and who are similar to patients included in the FREEDOM Trial. In addition, denosumab was found to be cost-effective in population currently reimbursed in Europe with T-score</=-2.5 or prevalent vertebral fracture, aged 60years and above. Additional data are needed on the relative cost-effectiveness compared with other anti-osteoporotic agents and on the long-term safety of denosumab.

Disciplines :

Special economic topics (health, labor, transportation...)
Rheumatology

Author, co-author :

Hiligsmann, Mickaël ; Université de Liège - ULiège > HEC-Ecole de gestion : UER > Economie industrielle

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Language :

English

Title :

Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.

Publication date :

2010

Journal title :

BONE

ISSN :

8756-3282

eISSN :

1873-2763

Publisher :

Elsevier Science, New York, United States - New York

Volume :

Pages :

34-40

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 12 April 2010

Statistics

Number of views

132 (5 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Cummings S.R., Martin J.S., McClung M.R., Siris E.S., Eastell R., Reid I.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
Drummond M., Sculpher M., O'Brien B., Stoddart G., Torrance G. Methods for the economic evaluation of health care programmes 2007, Oxford University Press, New-York. 3th edition.
Briggs A., Claxton K., Sculpher M. Decision modelling for health economic evaluation 2007, Oxford University Press, New-York. 2nd edition.
Borgstrom F., Kanis J.A. Health economics of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008, 22:885-900.
Cleemput I., van Wilder P., Huybrechts M., Vrijens F. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 2009, 12:441-449.
Zethraeus N., Borgstrom F., Strom O., Kanis J.A., Jonsson B. Cost-effectiveness of the treatment and prevention of osteoporosis-a review of the literature and a reference model. Osteoporos Int 2007, 18:9-23.
Hiligsmann M., Ethgen O., Bruyere O., Richy F., Gathon H.J., Reginster J.Y. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 2009, 12:687-696.
Hiligsmann M., Bruyere O., Ethgen O., Gathon H.J., Reginster J.Y. Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. Bone 2008, 43:991-994.
Reginster J.Y., Gillet P., Gosset C. Secular increase in the incidence of hip fractures in Belgium between 1984 and 1996: need for a concerted public health strategy. Bull World Health Organ 2001, 79:942-946.
Kanis J.A., Brazier J.E., Stevenson M., Calvert N.W., Lloyd Jones M. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2002, 6:1-146.
Klotzbuecher C.M., Ross P.D., Landsman P.B., Abbott T.A., Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000, 15:721-739.
Johnell O., Kanis J.A., Oden A., Sernbo I., Redlund-Johnell I., Petterson C., et al. Fracture risk following an osteoporotic fracture. Osteoporos Int 2004, 15:175-179.
Kanis J.A., Johnell O., De Laet C., Johansson H., Oden A., Delmas P., et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004, 35:375-382.
Institut National de Statistique. Démographie mathématique. Tables de mortalité 2006 et 2004-2006. Direction Générale Statistique et Information Economique. Belgium 2008.
Oden A., Dawson A., Dere W., Johnell O., Jonsson B., Kanis J.A. Lifetime risk of hip fractures is underestimated. Osteoporos Int 1998, 8:599-603.
Cauley J.A., Thompson D.E., Ensrud K.C., Scott J.C., Black D. Risk of mortality following clinical fractures. Osteoporos Int 2000, 11:556-561.
Johnell O., Kanis J.A., Oden A., Sernbo I., Redlund-Johnell I., Petterson C., et al. Mortality after osteoporotic fractures. Osteoporos Int 2004, 15:38-42.
Kanis J.A., Oden A., Johnell O., De Laet C., Jonsson B. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004, 15:108-112.
Kanis J.A., Oden A., Johnell O., De Laet C., Jonsson B., Oglesby A.K. The components of excess mortality after hip fracture. Bone 2003, 32:468-473.
Reginster J.Y., Gillet P., Ben Sedrine W., Brands G., Ethgen O., de Froidmont C., et al. Direct costs of hip fractures in patients over 60years of age in Belgium. Pharmacoeconomics 1999, 15:507-514.
Autier P., Haentjens P., Bentin J., Baillon J.M., Grivegnee A.R., Closon M.C., et al. Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int 2000, 11:373-380.
Bouee S., Lafuma A., Fagnani F., Meunier P.J., Reginster J.Y. Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries. Rheumatol Int 2006, 26:1063-1072.
Gabriel S.E., Tosteson A.N., Leibson C.L., Crowson C.S., Pond G.R., Hammond C.S., et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 2002, 13:323-330.
Melton L.J., Gabriel S.E., Crowson C.S., Tosteson A.N., Johnell O., Kanis J.A. Cost-equivalence of different osteoporotic fractures. Osteoporos Int 2003, 14:383-388.
Hiligsmann M., Ethgen O., Richy F., Reginster J.Y. Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 2008, 82:288-292.
Tosteson A.N., Gabriel S.E., Grove M.R., Moncur M.M., Kneeland T.S., Melton L.J. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 2001, 12:1042-1049.
Kanis J., Burlet N., Cooper C., Delmas P.D., Reginster J.Y., Borgstrom F., et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008, 19:399-428.
Kanis J.A., Johnell O., Oden A., Jonsson B., De Laet C., Dawson A. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 2000, 27:585-590.
Looker A.C., Wahner H.W., Dunn W.L., Calvo M.S., Harris T.B., Heyse S.P., et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998, 8:468-489.
Boonen S., Kaufman J.M., Reginster J.Y., Devogelaer J.P. Patient assessment using standardized bone mineral density values and a national reference database: implementing uniform thresholds for the reimbursement of osteoporosis treatments in Belgium. Osteoporos Int 2003, 14:110-115.
Marshall D., Johnell O., Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312:1254-1259.
Johnell O., Kanis J.A., Oden A., Johansson H., De Laet C., Delmas P., et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005, 20:1185-1194.
Miller P.D., Bolognese M.A., Lewiecki E.M., McClung M.R., Ding B., Austin M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43:222-229.
Bone H., Bolognese M., Yuen D., Kendler D., Miller P., Yang Y., et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Bone Miner Res 2009, 24(Suppl 1).
Belgian Center for Pharmacotherapeutic Information Accessed August 1, 2009. http://www.cbip.be/GGR/MPG/MPG_NI.cfm#MP_04090.pdf.
Hiligsmann M., Ethgen O., Bruyere O., Reginster J.Y. An economic evaluation of quantitative ultrasonometry as pre-screening test for the identification of patients with osteoporosis. Dis Manage Health Outcomes 2008, 16:429-438.
Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23:1296-1310.
Cramer J.A., Gold D.T., Silverman S.L., Lewiecki E.M. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007, 18:1023-1031.
Rabenda V., Mertens R., Fabri V., Vanoverloop J., Sumkay F., Vannecke C., et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008, 19:811-818.
Hiligsmann M., Bruyere O., Reginster J.Y. Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int 2010, 21:157-165.
Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Valeurs seuils pour le rapport coût-efficacité en soins de santé. Health Technology Assessment (HTA). Bruxelles: Centre fédéral d'expertise des soins de santé (KCE). KCE Reports 100B (D/2008/10.273/95).
Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. Br Med J 2001, 323:1300-1303.
Tosetson AN, Melton LJ, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, et al. National Osteoporosis Foundation Guide Committee. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008;4;437-47.
Strom O., Borgstrom F., Sen S.S., Boonen S., Haentjens P., Johnell O., et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries-an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007, 18:1047-1061.
Bombardier C., Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?. Ann Rheum Dis 1999, 58(Suppl 1):I82-I85.
Kanis J.A., Adams J., Borgstrom F., Cooper C., Jonsson B., Preedy D., et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone 2008, 42:4-15.
Kanis J.A., Johnell O., Oden A., Johansson H., McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19:385-397.
Kanis J.A., Oden A., Johansson H., Borgstrom F., Strom O., McCloskey E. FRAX and its applications to clinical practice. Bone 2009, 44:734-743.
Hunink M., Glasziou P., Siegel J., Weeks J., Pliskin J., Elstein A., et al. Decision making in health and medicine: integrating evidence and values 2001, Cambridge University Press, Cambridge.
Drummond M., Barbieri M., Cook J., Glick H., Lis J., Malik F., et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 2009, 12:409-418.
Hiligsmann M., Bruyere O., Reginster J.Y. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75years. Bone 2010, 46:440-446.
Hiligsmann M., Gathon H.J., Bruyere O., Ethgen O., Rabenda V., Reginster J.Y. Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 2010, [Electronic publication Ahead of Print].